#None #XtalPi #siRNA #Kodexia

XtalPi Introduces Kodexia™: Innovating Drug Development with AI

In a significant leap for drug discovery, XtalPi Holdings Limited has launched Kodexia™, the world's first integrated, closed-loop small interfering RNA (siRNA) platform. Combining generative AI with first-principles biological modeling, this innovative platform aims to redefine the landscape of drug development, especially for challenging diseases that conventional methods often overlook.

Founded by three MIT physicists in 2015, XtalPi has built a reputation for pioneering advancements in drugs and materials through the application of artificial intelligence and robotics. With the launch of Kodexia™, the company is not only advancing its technology but also positioning itself at the forefront of nucleic acid therapeutics.

What is Kodexia™?

Kodexia™ is designed to streamline and optimize various aspects of siRNA therapeutics, addressing crucial bottlenecks such as fragmented sequence design and complicated chemical modifications. The platform integrates several processes into one unified workflow, including:

• - Sequence Design
• - Chemical Modification
• - Experimental Validation
• - Extrahepatic Delivery Design
• - Intellectual Property Strategy

By employing a closed-loop computational design process, Kodexia™ enhances efficiency and precision in drug development. The system conducts over 500 in vitro and 30 in vivo experiments weekly, enabling rapid feedback and adjustments to optimize therapeutic candidates.

Enhancements in Efficacy Predictions

One of the standout features of Kodexia™ is its ability to significantly increase molecular design efficiency. Benchmarked internal data showcases that it nearly triples the effectiveness of molecular design compared to conventional workflows. Moreover, the first-round in vivo hit rate is exceeding 50% across multiple target programs, highlighting the platform's promise in delivering high-quality therapeutics.

The advancements presented by Kodexia™ stem from a sophisticated architecture known as siFormer, which integrates RNAi biological mechanisms with chemical principles. This integration allows researchers to balance multiple parameters effectively — such as potency, safety, and patentability — rather than focusing on single endpoints in isolation.

Real-World Applications

XtalPi’s efforts are validated by the speedy progress of six proprietary therapeutic programs now under Kodexia™, with one program on IgA nephropathy reaching non-human primate data within just seven months. This swift advancement not only signifies faster therapeutic development timelines but also demonstrates superior efficacy compared to existing clinical-stage options. As a result, the project is set for preclinical candidate selection much quicker than the industry standard.

Additionally, Kodexia™ enables co-optimization of dual-target siRNAs, addressing complex disease biology where single-target interventions may fall short. This holistic approach is particularly vital for targeting organs beyond the liver, such as the kidney and spleen, ensuring therapeutic agents reach problematic areas within the body where they can exert maximum efficacy.

Future Directions

With its capabilities, XtalPi continues to push the boundaries of what’s possible in RNA therapeutics. As the platform evolves, it targets diseases across various arenas — from metabolic and renal conditions to respiratory and neurological complications. Each internal program feeds invaluable data back into Kodexia™, fostering a continuous cycle of refinement and enabling the company to take a significant lead in RNA interference therapy.

In conclusion, Kodexia™ represents a landmark achievement for XtalPi, merging cutting-edge technologies to create a flexible, efficient, and powerful platform for drug discovery. The integration of advanced AI and biological modeling not only promises to expedite the development of critical therapies but also sets a new standard for innovation in the pharmaceutical industry. With the potential for improved patient outcomes globally, XtalPi remains committed to transforming the future of medicine through continuous exploration and collaboration.

• ---

About XtalPi: XtalPi Holdings Limited leverages quantum physics, AI, and robotics to offer intelligent R&D solutions across various industries, including pharmaceuticals, materials sciences, and more. Through its advanced digital platforms, XtalPi paves the way for groundbreaking innovations in drug and materials discovery.